Impact of influenza vaccine formulation with a detailed analysis of the cytokine response.
Vaccination provides the most effective method of limiting the impact of influenza. Inactivated influenza vaccines are available in three formulations and more information needs to be generated on how antigen presented in different vaccine formulations influences the subsequent immune response. In the present study, we have investigated the effect of two different influenza vaccine formulations on the resulting antibody and cytokine responses and compared these responses with influenza infection. Mice were vaccinated intramuscularly with one or two doses of whole or split virus vaccine or alternatively intranasally infected with influenza virus. Lymphocytes were isolated from spleen cells and stimulated in vitro for 24 or 72 h for analysis of cytokine profile at the gene expression and at the protein level. Additionally, whole blood was collected and the serum antibody response investigated by haemagglutination inhibition (HI) and enzyme-linked immunosorbent assay (ELISA). We found that one dose of whole virus vaccine induced higher antibody and cytokine responses and thus was more immunogenic in unprimed mice than split virus vaccine. Whole virus vaccine induced a strong IFN-gamma (type 1) immune response after one dose of vaccine and a more mixed cytokine response after the second dose. Split virus vaccine induced a type 2 response, particularly after two vaccine doses. Our results show that two doses of vaccine (both vaccine formulation) were more effective in induction of Th2 type of cytokines and thus indicate that both the formulation and also the number of vaccine doses substantially influences the magnitude and quality of the immune response.
Szyszko
E
E
Influenza Centre, The Gade Institute, University of Bergen, Bergen, Norway. ewa.szyszko@odont.uib.no
Brokstad
K
K
Cox
R J
RJ
Hovden
A-O
AO
Madhun
A
A
Haaheim
L R
LR
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood*; D000921:Antibody-Producing Cells / Q000276:immunology; D016207:Cytokines / Q000378:metabolism*; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D015870:Gene Expression; D006388:Hemagglutinins / Q000494:pharmacology; D053122:Influenza A Virus, H3N2 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D012333:RNA, Messenger / Q000378:metabolism*; D014611:Vaccination / Q000379:methods*
D000914:Antibodies, Viral; D016207:Cytokines; D006388:Hemagglutinins; D007252:Influenza Vaccines; D012333:RNA, Messenger